State of New Jersey Common Pension Fund D Grows Holdings in Bristol-Myers Squibb Company (BMY)

State of New Jersey Common Pension Fund D boosted its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 13.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,666,938 shares of the biopharmaceutical company’s stock after buying an additional 200,000 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.10% of Bristol-Myers Squibb worth $92,882,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Welch Investments LLC lifted its holdings in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares in the last quarter. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in Bristol-Myers Squibb by 29.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares in the last quarter. American National Bank lifted its holdings in Bristol-Myers Squibb by 11.7% during the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares in the last quarter. Finally, Heritage Trust Co acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth approximately $123,000. Institutional investors own 68.87% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “State of New Jersey Common Pension Fund D Grows Holdings in Bristol-Myers Squibb Company (BMY)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/10/09/state-of-new-jersey-common-pension-fund-d-grows-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company (BMY) opened at 64.81 on Monday. The stock has a market capitalization of $106.28 billion, a P/E ratio of 23.67 and a beta of 1.19. The company has a 50 day moving average of $61.56 and a 200-day moving average of $56.65. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $65.03.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.41%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Theodore R. Samuels II purchased 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

A number of equities research analysts have issued reports on BMY shares. UBS AG reiterated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday. BMO Capital Markets reissued a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, September 4th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price objective on the stock. in a research report on Tuesday, July 25th. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price objective (up from $63.00) on shares of Bristol-Myers Squibb in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $62.38.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply